Prognostic ability of the linear predictor in the PHOENIX trial cohort. The gene expression profiling (GEP) data from the activated B-cell–like (ABC) patients < 60 years old in the PHOENIX trial were used to generate linear scores for each patient. These scores were then used to stratify the patients into high- and low-risk cohorts. Kaplan–Meier plots of the progression free survival (PFS) rate of these patient subgroups is shown. (A) Both treatment arms combined; only patients designated as ABC by GEP. The PFS rate of these subgroups was also examined in each arm separately: (B) ibrutinib and (C) placebo. Red = high risk, blue = low risk. Finally, the effect of the drugs on PFS within the subgroups was assessed: (D) low risk and (E) high risk. Green = R-CHOP + placebo; purple = R-CHOP + ibrutinib.